Accessibility Menu
ViaDerma logo

ViaDerma(OTC) VDRM

Market Cap$246.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-100%
5 Year-99%
1 Year-80%
1 Month-50%
$0.00
-60.00%
-0.00Today
ViaDerma last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-14
ViaDerma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-50%USD 0.002026-08-07
1 month-50%USD 0.002026-07-15
3 month-50%USD 0.002026-05-15
Year to date+0%USD 0.002025-12-31
1 year-80%USD 0.002025-08-14
3 year-98.11%USD 0.012023-08-15
5 year-99.18%USD 0.022021-08-13
Since inception-100%USD 225.002009-08-06

ViaDerma Financials at a Glance

Market Cap

$246.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$600.88K

Net Income (TTM)

-$227.34K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-5.13 (Low)

Price

$0.00

Volume

15,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Oct 1, 2025

VDRM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ViaDerma

ViaDerma, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceutical products. The company also licenses its proprietary technology to other firms in the pharmaceutical sector, addressing various therapeutic areas.

Products and Services
  • Vitastem, a topical antibiotic effective for treating various skin ailments
  • Advanced topical antibiotics and antifungal treatments in development
  • Expanding pipeline including medical cannabis applications and anti-aging formulations
Growth Outlook
  • Ongoing development in multiple therapeutic areas enhances market potential
  • Strong focus on expanding product offerings to meet diverse healthcare needs
  • Strategic partnerships may drive future revenue growth and innovation
Financial Highlights
  • Recent quarterly revenue of $150,189 shows consistent performance
  • Trailing twelve months (TTM) gross profit margin remains high at 99.97%
  • Cash and cash equivalents increased to $1,491,343 in Q3 2024
ViaDerma, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, and is headquartered in Marina Del Rey, California. The company has established a strong foundation with its flagship product, Vitastem, which addresses a wide range of skin conditions. The commitment to innovation is evident in the ongoing development of new treatments, including advanced topical antibiotics and antifungal solutions. The growth outlook for ViaDerma is promising, with a focus on expanding its product pipeline to meet the evolving needs of the healthcare market. The company is actively pursuing strategic partnerships that could enhance its market presence and drive future revenue growth. Financially, ViaDerma has demonstrated resilience, with a recent quarterly revenue of $150,189, reflecting consistent performance. The TTM gross profit margin remains impressively high at 99.97%, indicating effective cost management and strong product demand. Additionally, the increase in cash and cash equivalents to $1,491,343 in Q3 2024 provides a solid liquidity position to support ongoing operations and development initiatives. Overall, ViaDerma, Inc. presents a compelling opportunity for investors interested in the pharmaceutical sector, particularly in companies focused on innovative solutions for diverse therapeutic needs.
AI Generated • Jul 31, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Chris Ayo Otiko, PhD

Website

www.viaderma.com

Headquarters

Las Vegas, NV 89119, US

VDRM Financials

Key Financial Metrics (TTM)

Gross Margin

99.97%

Operating Margin

30.85%

Net Income Margin

0.68%

Return on Equity

-0.48%

Return on Capital

41.53%

Return on Assets

0.32%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$246.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.23B

Volume

15.00K

Avg. Volume

107.67K

Financials (TTM)

Gross Profit

$600.68K

Operating Income

-$145.83K

EBITDA

-$145.64K

Operating Cash Flow

-$506.84K

Capital Expenditure

$0.00

Free Cash Flow

-$506.84K

Cash & ST Invst.

$1.49M

Total Debt

$1.86M

ViaDerma Performance Analysis

ViaDerma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 514,007N/A
20222022-12-31USD 540,6485.2%
20232023-12-31USD 600,49811.1%
20242024-12-31USD 450,499-25.0%
ViaDerma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-0.1%
Q12024-03-310.3%
Q22024-06-30-0.2%
Q32024-09-300.0%
ViaDerma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.00N/A
20222022-12-31USD 0.00N/A
20232023-12-31USD 0.00N/A
20242024-12-31USD -0.00N/A
ViaDerma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-100.0%
Q12024-03-31N/A
Q22024-06-30-100.0%
Q32024-09-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$150.19K

-0.0%

Gross Profit

$150.14K

-0.0%

Gross Margin

99.97%

N/A

Market Cap

$246.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.29K

N/A

Employees

75

N/A

Net Income

-$321.55K

-906.1%

EBITDA

-$294.40K

-606.4%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$1.49M

+15005.3%

Total Debt

$1.86M

+476.9%

Accounts Receivable

$4.00K

-99.6%

Inventory

$2.25M

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.86M

+476.9%

Return on Assets

0.32%

N/A

Return on Invested Capital

1.50%

N/A

Free Cash Flow

-$874.84K

-2916033.3%

Operating Cash Flow

-$874.84K

-2916040.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SFLMSFLMaven Corp.
$0.00+0.00%
GSACGelStat Corporation
$0.00+0.00%
GPFTGrapefruit USA, Inc.
$0.00+33.33%
LRSVLink Reservations Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About VDRM

What is the current price of ViaDerma?

ViaDerma is trading at $0.00 per share.

What is the 52-week range for ViaDerma?

Over the past 52 weeks, ViaDerma has traded between $0.00 and $0.01.

How much debt does ViaDerma have?

As of the most recent reporting period, ViaDerma reported total debt of $5.91M.

How much cash does ViaDerma have on hand?

ViaDerma reported $11.86K in cash and cash equivalents in its most recent financial results.

What is ViaDerma’s dividend yield?

ViaDerma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services